A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
Terremoto Biosciences Inc.
Ensem Therapeutics
Atavistik Bio, Inc
BeOne Medicines
Eli Lilly and Company
Blueprint Medicines Corporation
Avenzo Therapeutics, Inc.
AstraZeneca